- Investing.com
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Metrics to compare | SRZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRZNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −3.4x | −0.5x | |
PEG Ratio | 0.03 | −0.16 | 0.00 | |
Price/Book | 16.5x | 2.3x | 2.6x | |
Price / LTM Sales | 8.0x | 156.6x | 3.3x | |
Upside (Analyst Target) | 238.2% | 141.1% | 42.8% | |
Fair Value Upside | Unlock | 7.5% | 6.5% | Unlock |